Cargando…
Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges
At present, studies have found that c-Met is mainly involved in epithelial-mesenchymal transition (EMT) of tumor tissues in urologic neoplasms. Hepatocyte growth factor (HGF) combined with c-Met promotes the mitosis of tumor cells, and then induces motility, angiogenesis, migration, invasion and dru...
Autores principales: | Su, Pengxiao, Zhang, Ming, Kang, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028134/ https://www.ncbi.nlm.nih.gov/pubmed/36959792 http://dx.doi.org/10.3389/fonc.2023.1071030 |
Ejemplares similares
-
Opportunities and challenges of targeting c-Met in the treatment of digestive tumors
por: Zhang, Zhengchao, et al.
Publicado: (2022) -
CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future
por: Zhang, Zhengchao, et al.
Publicado: (2022) -
Targeting integrin α5β1 in urological tumors: opportunities and challenges
por: Zhou, Xuming, et al.
Publicado: (2023) -
The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer
por: Liao, Haiyan, et al.
Publicado: (2021) -
Met in Urological Cancers
por: Miyata, Yasuyoshi, et al.
Publicado: (2014)